Total
0
Shares
Aeris Environmental (ASX:AEI) - Non Executive Chairman, Maurie Stang
Non Executive Chairman, Maurie Stang
Source: Inclean
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sanitiser company, Aeris Environmental (AEI) has reported record sales revenue of over $4 million for the March quarter, due to COVID-19
  • It has also booked $4.1 million sales for the month of April alone
  • The company’s current revenue run rate for the 2020 financial year is now expected to be over $13 million
  • This month, Aeris completed a $12 million placement that saw strong demand from leading institutional and sophisticated investors
  • Aeris Environmental is down 5 per cent and shares closed at 57 cents each

Sanitiser company, Aeris Environmental (AEI) has reported a record sales revenue of over $4 million for the March quarter, due to the COVID-19 pandemic.

In the past nine months, Aeris has seen a sales revenue of $7.2 million. It has also booked $4.1 million in sales for April alone, with more than $2 million additional orders received.

The company’s current run rate for the 2020 financial year is now expected to be in excess of $13 million.

This month, the company completed a $12 million placement that had strong demand from leading institutional and sophisticated investors.

“Aeris is currently debt-free, cash positive and profitable,” the company said.

The company has expanded its Board with the appointment of Michael Ford, who is currently the Chief Financial Officer (CFO) of News Corp Australia. Micheal has over 30 years of experience in strategy and financial roles.

Aeris said it is on track to increase production, both domestically and internationally. Its products AerisGuard, Aeris Active and Actisan are quickly achieving international registrations and approvals due to COVID-19.

Aeris Environmental ended the day 5 per cent in the red with shares trading for 57¢ each.

AEI by the numbers
More From The Market Herald
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).
Noxopharm (ASX:NOX) - CEO, Dr Graham Kelly

" Noxopharm (ASX:NOX) granted Australian and European patents

Noxopharm (NOX) has been granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy.

" ACCC granted injunction to block Virtus Health’s (ASX:VRT) purchase of IVF clinics

Australia’s Federal Court has granted the ACCC an interlocutory injunction to temporarily stop Virtus Health (VRT) from acquiring a string of fertility clinics.